Aims/hypothesis. 'The Cost of Diabetes in EuropeType II study' is the first coordinated attempt to measure total healthcare costs of Type II (non-insulindependent) diabetes mellitus in Europe. The study evaluated more than 7000 patients with Type II diabetes in eight countries -Belgium, France, Germany, Italy, the Netherlands, Spain, Sweden and the United Kingdom. Methods. A bottom-up, prevalence-based design was used, which optimised the collection of data at the national level while maintaining maximum international comparability. Effort was made to ensure consistency in terms of data specification, data collection tools and methods, sampling design, and the analysis and reporting of results. Results are reported for individual countries and in aggregate for the total study population. Results. The total direct medical costs of Type II diabetes in the eight European countries was estimated at EUR 29 billion a year (1999 values). The estimated average yearly cost per patient was EUR 2834 a year. Of these costs, hospitalisations accounted for the greatest proportion (55%, range 30-65%) totalling EUR 15.9 billion for the eight countries. During the 6-month evaluation period, 13% of the Type II diabetic patients were hospitalised, with an average of 23 days in hospital projected annually. In contrast, drug costs for managing Type II diabetes were relatively low, with antidiabetic drugs and insulin accounting for only 7% of the total healthcare costs for Type 11 diabetes. Conclusionlinterpretation. Type 11 diabetes mellitus is a common disease and the prevalence is expected to increase considerably in the future, especially in developing countries. Current comprehensive economic data on the costs of diabetes are required for policy decisions to optimise resource allocation and to evaluate different approaches for disease management. [Diabetologia (2002) 45:S5-S 12] 
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Diabetes mellitus is a common disease and its prevalence is expected to increase in the future, especially in developing countries [1, 2] . As recently as 1995, an estimated 135 million peop1e worldwide were affected by diabetes and by the year 2025, this figure is projected to increase to approximately 300 million [3] . The majority of these diabetic patients (over 90%) suffer from Type II (non-insulin-dependent) diabetes mellitus, which is by nature, a progressive disorder with a slow and insidious onset. As a consequence, the condition is frequently under reported [4] and, of the estimated 15.6 million adult diabetic patients in the United States, an estimated 5.4 million cases remain undiagnosed [5] . S6 The control of Type II diabetes represents a considerable therapeutic challenge. The results of recent landmark studies, such as the United Kingdom Prospective Diabetes Study (UKPDS) [6] have shown that the relationship between glycaemic control and chronic complications is more complex than previously assumed. Long-term glycaemic control with currently available therapies remains an elusive target due to the progressive nature of the condition. Moreover, glycaemic control as evidenced by the reduction of HbA 1c with existing agents was found to have a weak and non-significant effect on the incidence of cardiovascular complications, although a correlation with the reduction of microvascular complications was noted. Consequently, one of the important messages to emerge from the study was that the management of Type II diabetes must be aimed at the comorbidities associated with the condition. Control of factors beyond the management of glycaemia (e.g. hypertension, hyperlipidaemia, insulin resistance, obesity) is vital in reducing the macrovascular complications.
Over the last 30 years, medical expenditure has increased throughout the world at a considerably faster rate than other sectors of the economy [7, 8] . It is estimated that the care of people with diabetes mellitus ac counts for 4 to 5% of the total health budget of the United Kingdom. [9] Arecent study by the American Diabetes Association showed that in 1997, diabetes accounted for $44.1 billion in direct healthcare expenditures, $37.1 billion in lost productivity due to disability and $17.0 billion from lost productivity due to premature mortality [10] . Of the diabetic complications, cardiovascular disease by far was found to have the greatest proportion of direct costs and more than half the mortality-related costs of the condition [10] . In arecent paper [11] it was shown that the per-person annual costs associated with Type II diabetes increased by more than 50% when cardiovascular complications started to appear, and by 360% when a major cardiovascular event occurred. Abnormal renal function increased diabetes treatment costs by 65%, and end-stage renal disease by 771 %. Due to the large number of complications associated with diabetes, diabetic patients account for 1 in every $7 spent on healthcare in the United States [12] .
Up-to-date and comprehensive economic data on the costs of diabetes are required for policy decisions, in order to optimise the allocation of resources and to evaluate the success of different approaches for disease management. While the economic aspects of Type II diabetes have been widely studied in the United States, information from Europe has been fairly limited until recently. There have been a few studies from European countries, for example two from Sweden [13, 14] and two from the United Kingdom [15, 16] . Although the information is difficult to compare and contrast, due to inconsistencies in re-B. Jönsson: Revealing the cost of Type II diabetes in Europe search objectives, methods and the data sources used, all studies highlight the substantial healthcare costs associated with diabetes. For example, these and many other studies do not make a distinction between Type I (insulin-dependent) and Type II (non-insulindependent) diabetes mellitus. While these separate conditions have similar long-term consequences, they affect different, albeit overlapping age groups and require different treatment strategies. The approach taken to measure the cost of diabetes is also variable. Some studies estimate the cost of diabetes, while others measure the total healthcare costs for diabetic patients, including both diabetes-related and non-diabetes-related events. Furthermore, some studies use the main diagnosis to attribute costs to diabetes, while other studies use aetiological fractions.
The CODE-2 study is the first coordinated attempt to measure the cost of people with Type II diabetes in Europe. This study measured total healthcare costs for more than 7000 people with Type II diabetes in eight European countries -Belgium, France, Germany, Italy, the Netherlands, Spain, Sweden and the United Kingdom using a bottom-up, prevalence-based design. A number of secondary objectives were also addressed, including: the distribution of total cost and the main components of cost (ambulatory care, drugs and hospitalisation); a review of current management practice; an assessment of the impact of complications on cost; and from the patient perspective, consideration of quality of life, satisfaction with treatment and self testing.
The collection of data directly from patients to assess the health-related quality of life (HRQoL) associated with the disease added another unique and important aspect to the study [17] . Whereas the primary objective focused on measuring the consequences of the condition with respect to direct healthcare expenditure, the secondary objectives considered areas of possible intervention, providing opportunities to maximise future use of resources.
Subjects and methods
Study design. The design of the study ( Fig. 1 ) was developed in consultation with an extensive panel of more than 100 experts inc1uding diabetologists, endocrinologists, health economists, general or primary-care practitioners and epidemiologists. In the design and implementation process, effort was made to ensure consistency across the eight countries in terms of data specification, data collection tools and methods, sampling design, and the analysis and reporting of results. Data was collected between J anuary 1999 and J une 1999 and covered a minimum period of 6 months, retrospectively. Estimates of healthcare utilisation and costs were projected for a 12-month period. Design modifications in accordance with differences in national healthcare systems were made when necessary, although limited as much as possible. The study design optimised the collection of data at the national level while maintaining maximum international comparability. After consultation with independent national experts and a review of existing epidemiological data, four of the eight countries (Belgium, France, Germany, and Italy) decided to collect data using stratified sampling techniques. Prior to the collection of CODE-2 data, Belgium, Germany, and Italy did a national survey of physicians, to ascertain the prevalence of known complications of Type II diabetes. In contrast, France used anational survey (ECODIA) [18] , which included a representative sampie of more than 4000 patients with Type II diabetes, to derive the sampling weights for the stratification. All definitions of microvascular and macrovascular complications were consistent across the four countries. These definitions are reported elsewhere in this supplement [19] . The remaining four countries collected data using a random sampling approach on the basis of known complications of Type II diabetes.
Study protocol. The data was collected by means of two questionnaires specially designed for practitioners and patients: the general practitioner (GP) questionnaire was used to collect information on direct medical resource utilisation and clinical data based on practitioner-held recards; and the patient questionnaire provided complimentary socio-economic information.
Data collected from practitioners included clinical, economic and demographic information, while data collected from patients included indirect and direct non-medical resource use, quality of life (QoL), satisfaction with current diabetes treatment, and information on self-testing of blood and urine sugar concentrations.
The overall direct healthcare costs were calculated by multiplying the quantities of the resource used with the unit price of each resource. To determine the direct cost of the Type II diabetic patients who were sampled, estimates of the number of physician visits, paramedical visits, tests and procedures, hospitalisations, days in hospital, emergency room visits and drug use were multiplied by a unit cost for each country (Table I) . In general, the costs far standard resources are relatively similar between the countries in the study and any variation is usually the result of differences in accounting procedures. For example, the baseline costs for GP visits in Sweden appear rela-I Results tively high; however, the value includes all the costs associated with an average visit, including all tests and procedures. The costs for these tests and procedures are calculated separately in other countries. To extrapolate the sampie costs to population size in order to calculate the total direct healthcare cost far each country, the per-patient costs were multiplied by national prevalence weights:
• PjxQi= Costi • Costjxprevalence weights = population cost • P = price, Q = resource use, and i=l-n (where n = number of cost items)
All local currency total costs were converted to Euros using the official Euro conversion rate as of January I, 1999. However, due to variations in the healthcare system in Germany, this extrapolation method using the values in Table 1 was not applicable for visits to GPs, diabetologists, or other specialists. These values included only the cost of the visit itself and the fees for each procedure are at an additional cost.
Results
Patients. The demographie data from CODE-2 are detailed in Table 2 and the Type II diabetes prevalenee data, which was used for extrapolation of sampIe eosts, are presented in Table 3 . The demographies of the study population were relatively similar between eaeh of the eountries with a few notable exeeptions. The study population of the United Kingdom had a higher proportion of male than female patients in eomparison with the other eountries. In addition, the time since diagnosis was higher than the 9-year average in Italy (13 years) and lower among the Dutch study population (6 years). The average age and body mass index (BMI) data were similar across all eight countries. The majority of patients recruited in the study were older than 65 years of age and were receiving treatment with oral antidiabetic agents (59%) (Fig. 2) . The greatest proportion of oral pharmaeotherapy was observed in France (84.69%) and the smallest in Sweden (42.45%). eral population was estimated to range from 1.7% in the Netherlands to 4.2% in Germany (Table 3) . On average, 3% of the population with Type II diabetes in the countries surveyed accounted for 5% of the total healthcare expenditure [25] , where available data from the Organisation far Economic Co-Operation and Development (OECD) was used to estimate the percentage of total healthcare budget spent on Type II (Table 4) . Comparing this study with the Ameriean study [12] , some differenees ean be notieed. Whereas the average prevalenee in the European eountries was 3%, the prevalenee in the United States was 4.5%. Furthermore, diabetic patients aeeounted for a larger share of the total health eare expenditures in the United States eompared to Europe (15% vs 5%). However, it is important to note the danger in eomparing studies earried out in different eountries in different years using different methodology. For example, the Ameriean study used a database as the main data souree, it was earried out in 1992, it included both Type I and Type II diabetes and more resourees than the CODE-2 study (e.g. dental eare and medieal equipment). In addition, relatively expensive inpatient eare aeeounted for a larger fraetion in the United States eompared to the European average (63% vs 55%).
Distribution 01 costs.
To investigate the distribution of eosts, resouree use was separated into three eategones:
(I) ambulatory eosts were defined as the sum of all eosts of visits to GPs, diabetologists and other speeialists (e.g. eardiologists), paramedieal praetitioners (e.g. physiotherapists, nurses, dieticians), aeeident and emergeney departments, and all tests and proeedures (e.g. blood tests, blood pressure measurements, ete); (2) hospitalisation eosts were defined as the sum of eosts of all admissions to hospital (for example, based on length of stay, DRG: diagnosis-related group or ICD-9: International Classifieation of Diseases); (3) drug eosts, defined as the sum of eosts of all drugs preseribed by GPs and speeialists in outpatient settings. Table 8 projected from 6-month survey data The distribution of the overall direct healthcare costs for all countries in the CODE-2 study is shown in Figure 3 the direct costs per patient represented by country and for the total CODE-2 population are illustrated in Table 5 and mean per patient cost by treatment type is detailed in Table 6 . Hospitalisations accounted for the greatest proportion of costs (55%, range 30-65%). In total, 13% of the study population were hospitalised in the 6-month study period. (Table 7) . Of the categories investigated, ambulatory S12 costs represented the smallest proportion of overall direct healthcare costs (18%) (Fig. 3) . The overall cost of drug therapy in these patients of EUR 7.9 billion represented 27% of the total healthcare costs. Although over 60% of patients were receiving oral antidiabetic agents, representing the largest primary treatment receiving drug therapy, the cost of these drugs accounted for only 4% of the total healthcare costs. When the components of the total drug cost category were considered in isolation, cardiovascular and lipid-Iowering agents represented the largest proportion (42%) with oral antidiabetic drugs accounting for only 13% and insulin 11 % of total drug costs (Fig. 4, Table 8 ).
Discussion
For the first time, the CODE-2 study has shown a comprehensive and practical insight into the costs of people with Type II diabetes across different European countries. The design of the study allowed for the direct comparison of international data on healthcare costs. The 6-month retrospective design could have some disadvantages. Recall bias could have been a problem but since the questionnaires relied mostlyon stored information, such as medical records, this problem is minor. Collecting information during a six month period and extrapolating to one year disregards any seasonal variation which might exist. The CODE-2 study showed that more than 10 million people with Type II diabetes across eight European countries cost over EUR 29 billion in 1999. Of the direct costs, hospitalisation alone accounted for the 1argest proportion, while drug costs for managing the disease were relatively low. Indeed, the oral drug therapy for the management of glycaemic control accounted for about 4% of overall costs in Type II diabetic patients. The single factor having the largest impact on costs of patients with Type II diabetic is the presence of different diabetes-related late complications. The findings from the CODE-2 study therefore confirm that in all eight of the European countries studied, Type II diabetes is a costly and burdensome disease.
